Dasher Neuroscience Press Releases
Breaking News and Milestones

Corporate Achievements and Awards

Clinical and Research Updates

YODA-KY (7829) YA-101 Receives Orphan Drug Designation in Japan, Following U.S. FDA Fast Track, Advancing Global Development Plans
TAIPEI, December 23, 2025 — YODA-KY (7829) announced today…
YODA-KY (7829) New Drug YA-101 Granted US FDA “Fast Track Designation” for the Treatment of Multiple System Atrophy
TAIPEI, December 22, 2025 —YODA-KY (7829) announced today (22nd)…
New Collaborations and Agreements

Taiwan’s First: YODA-KY (7829) AI-Developed Drug Prioritized by iLCT for Parkinson’s Disease Development; Signs MOUs with Australia and New Zealand to Expand Clinical Reach
TAIPEI, March 27, 2026 — Focusing on the use of artificial…

YODA-KY (7829) Signs MOU with Norwegian Research Center to Join the Platform Trial HYDRA and Advance AI-Driven Parkinson’s Drug Development in Europe
Release Date: March 27, 2026
Focusing on the use…
